Evidence mapPaperPMID 39334832Full record

ArticleBiomolecules2024

Joanna Bartkowiak-Wieczorek, Agnieszka Bienert, Kamila Czora-Poczwardowska, Radosław Kujawski, Michał Szulc, Przemysław Mikołajczak, Anna-Maria Wizner, Małgorzata Jamka, Marcin Hołysz, Karolina Wielgus and 2 more

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Molecules (Basel, Switzerland) · 2025
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Joanna Bartkowiak-WieczorekPhysiology Department, Poznan University of Medical Sciences, 60-781 Poznan, Poland.ORCID 0000-0002-8347-0512
Agnieszka BienertDepartment of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, 60-781 Poznan, Poland.
Kamila Czora-PoczwardowskaDepartment of Pharmacology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.ORCID 0000-0003-2873-4746
Radosław KujawskiDepartment of Pharmacology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.ORCID 0000-0002-2389-0689
Michał SzulcDepartment of Pharmacology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.ORCID 0000-0003-3295-2789
Przemysław MikołajczakDepartment of Pharmacology, Poznan University of Medical Sciences, 60-806 Poznan, Poland.ORCID 0000-0002-1252-6523
Anna-Maria WiznerDepartment of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, 60-781 Poznan, Poland.
Małgorzata JamkaDepartment of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, 60-572 Poznan, Poland.ORCID 0000-0002-0257-6180
Marcin HołyszDepartment of Biochemistry and Molecular Biology, Poznan University of Medical Sciences, 60-781 Poznan, Poland.ORCID 0000-0003-2505-3582
Karolina WielgusDepartment of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, 60-572 Poznan, Poland.ORCID 0000-0003-0629-2991
Ryszard SłomskiDepartment of Biotechnology, Institute of Natural Fibres and Medicinal Plants National Research Institute, 60-630 Poznan, Poland.ORCID 0000-0001-5601-7002
Edyta MądryPhysiology Department, Poznan University of Medical Sciences, 60-781 Poznan, Poland.ORCID 0000-0002-0081-6558

Funding

National Center for Research and Development INNOMED/I/11/NCBR/2014
6 · The paper itself

Abstract

introduction

resultsVK-induced neuropathic pain was accompanied by decreased CB1R protein level and CB2R mRNA expression in the cortex. Gabapentin relieved pain and increased CB1R protein levels in the hippocampus compared to the vincristine group. Hippocampus CB1R protein expression increased with the administration of extract D (10 mg/kg, 40 mg/kg) and extract B (7.5 mg/kg, 10 mg/kg) compared to VK group. In the cerebral cortex CSL decreased CB1R protein expression (10 mg/kg, 20 mg/kg, 40 mg/kg of extract B) and mRNA level (5 mg/kg, 7.5 mg/kg of extract B; 20 mg/kg of extract D) compared to the VK-group.CB2R protein expression increased in the hippocampus after treatment with extract B (7.5 mg/kg) compared to the VK-group. In the cerebral cortex extract B (10 mg/kg, 20 mg/kg) increased CB2R protein expression compared to VK-group.

conclusionAlterations in cannabinoid receptor expression do not fully account for the observed behavioural changes in rats. Therefore, additional signalling pathways may contribute to the initiation and transmission of neuropathic pain. The

Indexed as

CannabisNeuralgiaPlant ExtractsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2AnalgesicsAnimalsCerebral CortexGabapentinGene Expression RegulationHippocampusMaleRatsRats, WistarVincristineAnalgesicsGabapentinPlant ExtractsReceptor, Cannabinoid, CB1Receptor, Cannabinoid, CB2Vincristinecannabidiol (CBD)Cannabis sativagabapentingene expressionvincristineΔ9-tetrahydrocannabinol (THC)

Identifiers

PMID39334832
PMCPMC11430414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.